Hepatitis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis B Virus Therapy
Reports from Kaohsiung Medical University, College of Medicine highlight recent research in hepatitis B virus therapy
July 9th, 2007
Researchers detail in "Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B," new data in hepatitis B virus. According to a study from Kaohsiung, Taiwan, "Adefovir dipivoxil (ADV)-resistant mutations have been identified in treating hepatitis B virus (HBV) infection. This study aimed to analyze the response, the incidence of ADV resistance and the virologic characteristics of ADV therapy." "A total of 29 CHB patients with confirmed lamivudine (LAM)-resistant HBV were treated with ADV for more than 52 weeks. Serum HBV DNA, HBV genotypes and sequences of HBV polymerase reverse-transcriptase domain were determined. Rates for the biochemical response,...
Source: Hepatitis Weekly (2007-07-09)
|
